FIORE, Mathieu; D'OIRON, Roseline; PILLOIS, Xavier; ALESSI, Marie-Christine

doi:10.1111/bjh.15087

Metadatos

Mostrar el registro completo del ítem

Licencia de uso del documento

FIORE, Mathieu

D'OIRON, Roseline

PILLOIS, Xavier
Biologie des maladies cardiovasculaires = Biology of Cardiovascular Diseases

Idioma

Article de revue

Este ítem está publicado en

British Journal of Haematology. 2018-04, vol. 181, n° 2, p. 173–182

Resumen en inglés

Glanzmann thrombasthenia (GT) is caused by inherited defects of the αIIb β3 platelet glycoprotein. This bleeding disorder can be treated with platelet transfusion therapy, but some patients will be immunized and begin to form anti-human leucocyte antigen (HLA) and/or anti-αIIb β3 antibodies. These antibodies can bind and interfere with the function of the transfused platelets, rendering treatment ineffective. However, platelet transfusion refractoriness attributable to HLA antibodies may be managed by the selection of compatible donors, although they are not always readily available, particularly in an emergency. Thus, anti-αIIb β3 antibodies represent one of the most severe complications in GT. Both genetic and environmental factors may contribute to the risk of anti-αIIb β3 development, but the underlying pathogenic mechanisms are still unknown. This review will summarize the current knowledge of the risk factors for development of anti-αIIb β3 antibodies in patients with GT and discuss how these findings may influence the clinical management of patients.< Leer menos

Palabras clave

Article RECHERCHE

Palabras clave en inglés

Autoantibodies

Glanzmann thrombasthenia

Humans

immunization

Immunization

platelet antibody

Platelet Glycoprotein GPIIb-IIIa Complex

Platelet Transfusion

rFVIIa

Risk Factors

Thrombasthenia

Transfusion Reaction

αIIbβ3